Gotistobart

Phase 3Small molecule

OOncoC4, Inc.

Gotistobart is one of 73 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Solid TumorEnrolling by invitation

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Solid TumorPhase 3

Enrolling by invitation

Competition

Competitive Landscape

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Almonertinib

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3

6 2

Glumetinib

HHaihe Biopharma Co., Ltd.

Phase 3

5 3

Gotistobart

OOncoC4, Inc.

Phase 3

1 4

Taletrectinib

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer

NCT05671510

Clinical

Trials by Indication[1]

Solid Tumor1 trial

Extension Trial to Study the Long-term Safety and Efficacy in Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in Gotistobart Trials

Enrolling by invitation·OOncoC4, Inc.·Phase 3·NCT07659379·20 enrolled

Non-Small Cell Lung Cancer1 trial

Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors

Active, not recruiting·OOncoC4, Inc.·Phase 3·NCT05671510·630 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Gotistobart. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gotistobart compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gotistobart. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — OncoC4, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: OOncoC4, Inc.

Gotistobart

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Solid Tumor1 trial

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News